Saadiah Ahmed, DO
Endocrinology, Diabetes & Metabolism · Saint Clair Shores, MINPI 1649486044
Payments from drug & device makers
Across 150 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$380
- Amgen$251
- Dexcom, Inc.$243
- AbbVie$180
- Sanofi-aventis U.S. LLC$176
- Abbott$158
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,575100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $380 |
| Amgen(2 entities) | 13 | $251 |
| Dexcom, Inc. | 14 | $243 |
| AbbVie | 10 | $180 |
| Sanofi-aventis U.S. LLC | 10 | $176 |
| Abbott | 8 | $158 |
| Insulet Corporation | 7 | $143 |
| Medtronic(2 entities) | 7 | $125 |
| Lilly USA, LLC | 6 | $112 |
| Merck | 7 | $109 |
| Boehringer Ingelheim | 4 | $93 |
| Mannkind Corporation | 5 | $79 |
| Alvogen Inc | 3 | $49 |
| Tolmar, Inc. | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $38 |
| Amryt Pharma Holdings Ltd | 2 | $36 |
| Ascendis Pharma Endocrinology Inc | 2 | $36 |
| Embecta Corp. | 2 | $35 |
| BD | 2 | $31 |
| Recordati_rare_diseases_inc. | 1 | $30 |
| Johnson & Johnson | 2 | $30 |
| BETA Bionics, Inc. | 2 | $27 |
| Averitas Pharma Inc. | 1 | $26 |
| AstraZeneca | 2 | $25 |
| Shire North American Group Inc | 2 | $24 |
| Radius Health, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Bayer | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Tandem Diabetes Care, Inc. | 2 | $9 |
How this compares
$2,587 in reported general payments places this provider in the 50th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 403 | $754,183 |
| TrulicityDulaglutide | 229 | $385,196 |
| JardianceEmpagliflozin | 250 | $362,440 |
| MounjaroTirzepatide | 213 | $241,465 |
| Tresiba Flextouch U-100Insulin Degludec | 122 | $91,009 |
| FarxigaDapagliflozin Propanediol | 69 | $87,246 |
| JanuviaSitagliptin Phosphate | 52 | $72,602 |
| Novolog FlexpenInsulin Aspart | 178 | $61,256 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $55,073 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $45,119 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 235 | $41,655 |
| TradjentaLinagliptin | 38 | $34,355 |
| Humalog Kwikpen U-100Insulin Lispro | 90 | $31,324 |
| Humulin R U-500Insulin Regular, Human | 13 | $27,417 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 168 | $21,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $380 | $772,586454 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi, Humalog | $112 | $645,226476 claims |
| Boehringer IngelheimJardiance, Tradjenta | $93 | $396,795288 claims |
| AstraZenecaFarxiga | $25 | $87,24669 claims |
| MerckJanuvia | $109 | $72,60252 claims |
| AbbVieSynthroid | $180 | $12,737157 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $21 | $11,012833 claims |
| Sanofi-aventis U.S. LLCLantus | $176 | $4,40028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Saint Clair Shores
- Michael BrennanSaint Clair Shores$433K
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.